Crinetics shareholders elect directors, ratify auditor, and approve say-on-pay on annual basis

Crinetics Pharmaceuticals, Inc.

Elected three Class II directors: Caren Deardorf, Weston Nichols (Ph.D.), Stephanie Okey (M.S.) for 3-year terms.
Ratified BDO USA as independent auditor for FY2023 with 48,326,036 votes for, 3,916 against.
Advisory vote on executive compensation approved: 45,092,585 for, 1,192,212 against.
Advisory vote on say-on-pay frequency favored annual votes (41,312,125 for 1-year); company will hold annual votes.
Approximately 90% of outstanding shares (48,336,267) were present at the meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Crinetics Pharmaceuticals, Inc. shareholders approved Approval, on an advisory basis, regarding whether the stockholder vote to approve the compensation of the Company's named executive officers should occur every one, two or three years at the 2023-06-16 meeting.

Proposal: say on pay frequency
Outcome: passed
Meeting: 2023-06-16

Exact text from the filing

The Company’s stockholders approved, on an advisory basis, that the compensation of the Company’s named executive officers should occur every one, two or three years. The results of such vote were: Votes For 1 Yr. Votes for 2 Yr. Votes for 3 Yr. Abstentions Broker Non-Votes 41,312,125 1,577 403,696 4,570,396 2,048,473

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Crinetics Pharmaceuticals, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2023-06-16 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-16

Exact text from the filing

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were: Votes For Votes Against Abstentions Broker Non-Votes 45,092,585 1,192,212 2,997 2,048,473

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Crinetics Pharmaceuticals, Inc. shareholders approved Election of three Class II directors to the Board of Directors for three year terms to expire at the 2026 annual meeting of stockholders at the 2023-06-16 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-16

Exact text from the filing

The Company’s stockholders approved the election of three Class II directors to the Board of Directors for three year terms to expire at the 2026 annual meeting of stockholders. The results of such vote were: Votes For Votes Withheld Broker Non-Votes Caren Deardorf 37,044,248 9,243,546 2,048,473 Weston Nichols, Ph.D. 44,252,003 2,035,791 2,048,473 Stephanie S. Okey, M.S. 36,802,418 9,485,376 2,048,473

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Crinetics Pharmaceuticals, Inc. shareholders approved Ratification of selection of BDO USA, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-16 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-16

Exact text from the filing

The Company’s stockholders ratified the selection of BDO USA, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023. The results of such vote were: Votes For Votes Against Abstentions Broker Non-Votes 48,326,036 3,916 6,315 0

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-029176

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.